Diagnostic Value and Short-Term Prognosis Assessment of Copeptin in Non-ST-Elevation Acute Coronary Syndrome

This study explored the early diagnosis and prognostic value of copeptin in non-ST-segment elevation acute coronary syndrome (NSTE-ACS). 171 patients with chest pain or myocardial ischemia symptoms were enrolled. Patients with NSTE-ACS were further divided into the non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA). All NSTE-ACS patients were followed up to record the occurrence of Major Adverse Cardiovascular Events (MACEs). Serum copeptin concentration in the NSTE-ACS group was significantly higher than that in the control group. The Area under the curve (AUC) value of copeptin in the diagnosis of NSTE-ACS was 0.798. The combined AUC value of copeptin and hypersensitive troponin I (hs-TnI) to NSTE-ACS increased to 0.930. In addition, copeptin and hs-TnI have been proven to be independent risk factors for MACEs in patients with NSTE-ACS. The use of copeptin in combination with conventional myocardial markers contributes to the early diagnosis and short-term prognosis assessment of NSTE-ACS.